Søren Fast

Summary

Affiliation: Odense University Hospital
Country: Denmark

Publications

  1. ncbi The majority of Danish nontoxic goitre patients are ineligible for Levothyroxine suppressive therapy
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Odense C, Denmark
    Clin Endocrinol (Oxf) 69:653-8. 2008
  2. ncbi Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, DK 5000 Odense C, Denmark
    Eur J Endocrinol 160:517-28. 2009
  3. ncbi Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
    J Nucl Med 50:732-7. 2009
  4. ncbi Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
    Clin Endocrinol (Oxf) 72:411-6. 2010
  5. ncbi Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, DK 5000 Odense C, Denmark
    J Clin Endocrinol Metab 95:3719-25. 2010
  6. ncbi Radioiodine therapy of benign non-toxic goitre. Potential role of recombinant human TSH
    S Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Denmark
    Ann Endocrinol (Paris) 72:129-35. 2011
  7. ncbi [Icatibant is a new treatment option in life-threatening angioedema triggered by angiotensin-converting enzyme inhibitor]
    Søren Fast
    Øre næse hals Afdeling F, Odense Universitetshospital, 5000 Odense C, Denmark
    Ugeskr Laeger 173:2574-5. 2011
  8. ncbi Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy
    Steen Joop Bonnema
    Department of Endocrinology, Odense University Hospital, 5000, Odense C, Denmark
    Endocrine 40:344-53. 2011

Detail Information

Publications8

  1. ncbi The majority of Danish nontoxic goitre patients are ineligible for Levothyroxine suppressive therapy
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Odense C, Denmark
    Clin Endocrinol (Oxf) 69:653-8. 2008
    ..Our aim was to determine, in consecutive nontoxic goitre patients, the proportion ineligible for LT4-therapy. Exclusion criteria were set up in agreement with recent guidelines...
  2. ncbi Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, DK 5000 Odense C, Denmark
    Eur J Endocrinol 160:517-28. 2009
    ..Thus, although in its infancy, and still experimental, rhTSH-augmented (131)I therapy may profoundly alter the non-surgical treatment of benign non-toxic MNG...
  3. ncbi Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
    J Nucl Med 50:732-7. 2009
    ..The purpose of this study was to determine the optimal time interval between rhTSH and (131)I administration to enhance thyroid radioactive iodine uptake (RAIU)...
  4. ncbi Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
    Clin Endocrinol (Oxf) 72:411-6. 2010
    ..Reports of acute thyroid swelling and hyperthyroidism warrant safety studies evaluating whether these side-effects are dose dependent...
  5. ncbi Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy
    Søren Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, DK 5000 Odense C, Denmark
    J Clin Endocrinol Metab 95:3719-25. 2010
    ..Observations indicate that rhTSH has a preconditioning effect beyond increasing thyroid (131)I uptake. We test the hypothesis that an equivalent GVR might be obtained by an absorbed thyroid dose well below what has been used previously...
  6. ncbi Radioiodine therapy of benign non-toxic goitre. Potential role of recombinant human TSH
    S Fast
    Department of Endocrinology and Metabolism, Odense University Hospital, Denmark
    Ann Endocrinol (Paris) 72:129-35. 2011
    ..1mg rh-TSH or less is well tolerated. Based on these results we conclude that rh-TSH augmented ¹³¹I therapy is a promising new therapeutic principle allowing the tailoring of an optimal ¹³¹I therapy on the individual level...
  7. ncbi [Icatibant is a new treatment option in life-threatening angioedema triggered by angiotensin-converting enzyme inhibitor]
    Søren Fast
    Øre næse hals Afdeling F, Odense Universitetshospital, 5000 Odense C, Denmark
    Ugeskr Laeger 173:2574-5. 2011
    ..Randomised, controlled trials are warranted to document the efficacy of icatibant in ACE-i angioedema...
  8. ncbi Non-surgical approach to the benign nodular goiter: new opportunities by recombinant human TSH-stimulated 131I-therapy
    Steen Joop Bonnema
    Department of Endocrinology, Odense University Hospital, 5000, Odense C, Denmark
    Endocrine 40:344-53. 2011
    ..A major hindrance of widespread and routine use of rhTSH-stimulated (131)I-therapy is its present status as an off-label treatment...